Carteolol
- Atc Codes:C07AA15#S01ED05
- CAS Codes:51781-21-6#51781-06-7
- PHARMGKB ID:51781-21-6#51781-06-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Arteoptic; Belgium: Arteoptic, Carteol; Czech Republic: Arteoptic, Carteol; France: Carteabak, Carteol, Mikelan; Germany: Arteoptic, Carteol LA, Endak; Greece: Cardelol, Glautelol; Hungary: Fortinol; Italy: Carteabak, Carteol, Fortinol; Luxembourg: Carteol; Netherlands: Arteoptic, Carteabak, Teoptic; Poland: Arteoptic, Carteabak, Carteol; Portugal: Arteoptic, Carteabak, Physioglau; Romania: Carteol, Fortinol EP; Slovakia: Arteoptic, Carteol; Spain: Arteoptic, Elebloc, Mikelan.
North America
USA: Carteolol, Ocupress.
Latin America
Argentina: Cartens, Carteolol Skin, Elebloc, Poenglaucol.
Asia
Japan: Betamenol, Block B, Blokyleate, Cartelol, Carteolol T, Cystarol, Kalnonon, Lantelol, Mercatoa, Mikelan, Orukalol, Thiogule.
Drugs Combinations
Carteolol and Pilocarpine
Drug combinations
Chemistry
Carteolol Hydrochloride: C~16~H~24~N~2~O~3~ HCl. Mw: 328.83. (1) 2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride; (2) 5-[3-(tert-Butylamino)-2-hydroxypropoxy]-3,4-dihydrocarbostyril monohydrochloride. CAS-51781-21-6; CAS-51781-06-7 (carteolol)(1976).
Pharmacologic Category
Antiglaucoma Agents. (ATC-Code: C07AA15; S01ED05).
Mechanism of action
Blocks both β~1~- and β~2~-receptors and has mild intrinsic sympathomimetic activity. Reduces intraocular pressure by decreasing aqueous humor production. Has negative inotropic and chronotropic effects and can significantly slow AV nodal conduction.
Therapeutic use
Chronic open-angle glaucoma and intraocular hypertension.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to carteolol or any component of the formulation. Sinus bradycardia. Heart block greater than first-degree (except with functioning artificial pacemaker). Cardiogenic shock. Uncompensated cardiac failure. Bronchial asthma, bronchospasm, or chronic obstructive pulmonary disease. Pulmonary edema.
Warnings and precautions
In general, patients with bronchospastic disease should not receive β-blockers. Caution in diabetes mellitus (may potentiate hypoglycemia and/or mask signs and symptoms), compensated heart failure, myasthenia gravis, or peripheral vascular disease (including Raynaud’s). Systemic absorption and adverse effects might occur after ophthalmic administration. Should not be used alone in angle-closure glaucoma (has no effect on pupillary constriction). May cause fatigue, insomnia, confusion, and nightmares and clinically look like a major depression.